BrainSightAI

BrainSightAI operates at the intersection of neuroimaging software, clinical decision support, digital health, and neuroscience research. Its stated focus is narrower than general-purpose medical AI: VoxelBox applies AI, machine learning, connectomics, brain-tract visualisation, and co-registration to MRI and resting-state fMRI data, producing personalised brain maps for neurological and psychiatric investigation. Snowdrop extends the offering beyond imaging by collecting patient history and symptom data through a mobile interface. This combination gives the company a potentially differentiated workflow spanning patient-reported information, imaging analysis, and clinician interpretation. The business is positioned as an early-stage specialist rather than a scaled diagnostic platform: it is private, has an employee band of 11–50, and has raised $5.95 million across six recorded rounds. Its stated customer audiences include neurologists, psychiatrists, neurosurgeons, researchers, and clinical-study partners. The available comparable-company records do not identify distinct named competitors, so direct competitive benchmarking is limited. The main market risks are clinical validation, regulatory approval, integration into hospital workflows, and the need to demonstrate that personalised maps improve decisions beyond conventional MRI interpretation.

BrainSightAI’s trajectory shows a progression from early technical development toward a more capitalised neuroimaging platform. The company was founded in June 2019 and completed two pre-seed rounds in December 2019 and January 2020, including an $80,000 round. It then recorded a seed round with NetApp Excellerator in November 2020, followed by $750,000 led by Stanford Angels and Entrepreneurs India on Dec 16, 2021. A further $119,890 round led by Redstart Labs was announced on Jul 10, 2023. The key inflection point was Jan 8, 2025, when BrainSightAI announced $5 million from IAN Group, IvyCap Ventures, and Silverneedle Ventures; this represented roughly 84% of its structured cumulative funding. Product development has concentrated on VoxelBox, including its use for personalised 3D brain maps and complex MRI analysis, while Snowdrop broadens data collection into mobile patient assessment. Internship hiring suggests continued team-building rather than a mature expansion phase.